{"id":153050,"date":"2013-04-17T00:00:00","date_gmt":"2013-04-17T00:00:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/"},"modified":"2013-04-17T00:00:00","modified_gmt":"2013-04-17T00:00:00","slug":"des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/","title":{"rendered":"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement"},"content":{"rendered":"<p>Les quatre variantes g\u00e9n\u00e9tiques li\u00e9es au d\u00e9veloppement de la DMLA n'influeraient pas sur l'efficacit\u00e9 des traitements au Lucentis et \u00e0 l'Avastin.<\/p>\n<p>\u00a0<\/p>\n<p>Les variantes g\u00e9n\u00e9tiques CFH, ARMS2, HTRA1 et C3 favorisent l'apparition de la DMLA. Des chercheurs ont voulu savoir s'ils modifiaient aussi la r\u00e9ponse des patients aux traitements de la forme humide de la maladie. Cela aurait permis d'adapter les traitements au profil g\u00e9n\u00e9tique des patients.<\/p>\n<p>\u00a0<\/p>\n<p>Les chercheurs ont observ\u00e9 les g\u00e9notypes de 73 % des 1 149 participants \u00e0 l'\u00e9tude <em>Comparison of AMD Treatment Trials<\/em> (CATT). Ils les ont par la suite compar\u00e9s \u00e0 la r\u00e9ponse des patients aux traitements. Malheureusement, la comparaison n'a pas permis d'\u00e9tablir un lien entre les g\u00e8nes et la r\u00e9ponse aux traitements. Ce r\u00e9sultat confirme celui d'une \u00e9tude r\u00e9alis\u00e9e en 2012 par l'American Academy of Ophthalmology.<\/p>\n<p>\u00a0<\/p>\n<p>\u00ab\u00a0Notre \u00e9quipe de recherche g\u00e9n\u00e9tique continue d'esp\u00e9rer que des variantes g\u00e9n\u00e9tiques pr\u00e9disant la r\u00e9ponse des patients aux traitements de la DMLA seront bient\u00f4t identifi\u00e9es\u00a0\u00bb, soutient la D<sup>re<\/sup> Stephanie Hagstrom, chercheure principale de l'\u00e9tude CATT. \u00ab\u00a0Cela permettrait une avanc\u00e9e significative dans la capacit\u00e9 des ophtalmologistes d'individualiser les traitements.\u00a0\u00bb\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Source\u00a0: <a title=\"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement\" href=\"http:\/\/www.aao.org\/newsroom\/release\/20130213.cfm\">http:\/\/www.aao.org\/newsroom\/release\/20130213.cfm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les quatre variantes g\u00e9n\u00e9tiques li\u00e9es au d\u00e9veloppement de la DMLA n'influeraient pas sur l'efficacit\u00e9 des traitements au Lucentis et \u00e0 l'Avastin. \u00a0 Les variantes g\u00e9n\u00e9tiques CFH, ARMS2, HTRA1 et C3 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23133],"tags":[],"class_list":["post-153050","post","type-post","status-publish","format-standard","hentry","category-nouvelles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement - OptikNow\" \/>\n<meta property=\"og:description\" content=\"Les quatre variantes g\u00e9n\u00e9tiques li\u00e9es au d\u00e9veloppement de la DMLA n&#039;influeraient pas sur l&#039;efficacit\u00e9 des traitements au Lucentis et \u00e0 l&#039;Avastin. \u00a0 Les variantes g\u00e9n\u00e9tiques CFH, ARMS2, HTRA1 et C3 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2013-04-17T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement\",\"datePublished\":\"2013-04-17T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/\",\"name\":\"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"datePublished\":\"2013-04-17T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/04\\\/17\\\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement - OptikNow","og_description":"Les quatre variantes g\u00e9n\u00e9tiques li\u00e9es au d\u00e9veloppement de la DMLA n'influeraient pas sur l'efficacit\u00e9 des traitements au Lucentis et \u00e0 l'Avastin. \u00a0 Les variantes g\u00e9n\u00e9tiques CFH, ARMS2, HTRA1 et C3 [&hellip;]","og_url":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/","og_site_name":"OptikNow","article_published_time":"2013-04-17T00:00:00+00:00","author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement","datePublished":"2013-04-17T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"articleSection":["Nouvelles"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/","url":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/","name":"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"datePublished":"2013-04-17T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/04\/17\/des-genes-lies-au-developpement-de-la-dmla-mais-pas-a-son-traitement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Des g\u00e8nes li\u00e9s au d\u00e9veloppement de la DMLA, mais pas \u00e0 son traitement"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=153050"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153050\/revisions"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=153050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=153050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=153050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}